Bank of New York Mellon
ADCT icon

Bank of New York Mellon’s ADC Therapeutics ADCT Stock Holding History

Bank of New York Mellon’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$269K Buy
251,645
+49,391
+24% +$144K ﹤0.01% 4053
2026
Q1 		$758K Buy
202,254
+29,267
+17% +$115K ﹤0.01% 3382
2025
Q4 		$611K Buy
172,987
+14,293
+9% +$58K ﹤0.01% 3498
2025
Q3 		$635K Buy
158,694
+559
+0.4% +$1.76K ﹤0.01% 3462
2025
Q2 		$424K Sell
158,135
-1,331
-0.8% -$2.8K ﹤0.01% 3601
2025
Q1 		$225K Sell
159,466
-12,527
-7% -$21.3K ﹤0.01% 3838
2024
Q4 		$342K Buy
171,993
+9,750
+6% +$25.5K ﹤0.01% 3709
2024
Q3 		$511K Sell
162,243
-42,978
-21% -$136K ﹤0.01% 3507
2024
Q2 		$648K Buy
+205,221
New +$816K ﹤0.01% 3433

Other funds holding ADCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
SCTC
Sanibel Captiva Trust Company Sanibel, Florida $4.02B AUM 34.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
RWP
Revolve Wealth Partners Hackensack, New Jersey $965M AUM 22.88% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return
DIM
DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon's ADCT Position: Q2 2026 in Review

Bank of New York Mellon increased its ADC Therapeutics (ADCT) stake by 24% in Q2 2026, buying an estimated $144K and bringing the position to 251,645 shares worth $269K. The position accounts for ﹤0.01% of the portfolio, ranked #4053.

Bank of New York Mellon first reported a position in ADCT in Q2 2024 and has held it in 9 quarters since. The position peaked at $758K in Q1 2026. 42 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Bank of New York Mellon held 251,645 shares of ADC Therapeutics worth $269K as of Q2 2026.
  • Bank of New York Mellon bought 49,391 ADC Therapeutics shares in Q2 2026, an estimated $144K.
  • ADC Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4053 holding.
  • Bank of New York Mellon first reported a position in ADC Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Bank of New York Mellon's ADC Therapeutics position peaked at $758K in Q1 2026.
  • 42 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.